CORD-19:68a7101a90454172c91785d8c352f776a82df5d4 / 843469-843844 JSONTXT

{"project":"CORD-19-Sentences","denotations":[{"id":"T98920","span":{"begin":0,"end":176},"obj":"Sentence"},{"id":"T46896","span":{"begin":177,"end":375},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"The increasing number of new therapies for MS and the potential risk for a lack of response and/or serious adverse reactions make individualized therapy a high-priority for MS. Pharmacogenomics applies technologies such as gene expression profiling, single nucleotide polymorphism (SNP) screens, and proteomics in order to predict response to treatment and toxicity to drugs."}

{"project":"Epistemic_Statements","denotations":[{"id":"T1849","span":{"begin":0,"end":375},"obj":"Epistemic_statement"}],"text":"The increasing number of new therapies for MS and the potential risk for a lack of response and/or serious adverse reactions make individualized therapy a high-priority for MS. Pharmacogenomics applies technologies such as gene expression profiling, single nucleotide polymorphism (SNP) screens, and proteomics in order to predict response to treatment and toxicity to drugs."}

{"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T34","span":{"begin":0,"end":176},"obj":"Sentence"},{"id":"T35","span":{"begin":177,"end":375},"obj":"Sentence"}],"text":"The increasing number of new therapies for MS and the potential risk for a lack of response and/or serious adverse reactions make individualized therapy a high-priority for MS. Pharmacogenomics applies technologies such as gene expression profiling, single nucleotide polymorphism (SNP) screens, and proteomics in order to predict response to treatment and toxicity to drugs."}

{"project":"CORD-19-PD-UBERON","denotations":[{"id":"T3525","span":{"begin":43,"end":45},"obj":"Body_part"},{"id":"T3526","span":{"begin":173,"end":175},"obj":"Body_part"}],"attributes":[{"id":"A3525","pred":"uberon_id","subj":"T3525","obj":"http://purl.obolibrary.org/obo/UBERON_0001877"},{"id":"A3526","pred":"uberon_id","subj":"T3526","obj":"http://purl.obolibrary.org/obo/UBERON_0001877"}],"text":"The increasing number of new therapies for MS and the potential risk for a lack of response and/or serious adverse reactions make individualized therapy a high-priority for MS. Pharmacogenomics applies technologies such as gene expression profiling, single nucleotide polymorphism (SNP) screens, and proteomics in order to predict response to treatment and toxicity to drugs."}

{"project":"CORD-19-PD-MONDO","denotations":[{"id":"T5316","span":{"begin":43,"end":45},"obj":"Disease"},{"id":"T5317","span":{"begin":173,"end":175},"obj":"Disease"},{"id":"T32295","span":{"begin":43,"end":45},"obj":"Disease"},{"id":"T5280","span":{"begin":173,"end":175},"obj":"Disease"}],"attributes":[{"id":"A5316","pred":"mondo_id","subj":"T5316","obj":"http://purl.obolibrary.org/obo/MONDO_0005301"},{"id":"A5317","pred":"mondo_id","subj":"T5317","obj":"http://purl.obolibrary.org/obo/MONDO_0005301"},{"id":"A27146","pred":"mondo_id","subj":"T32295","obj":"http://purl.obolibrary.org/obo/MONDO_0005301"},{"id":"A7508","pred":"mondo_id","subj":"T5280","obj":"http://purl.obolibrary.org/obo/MONDO_0005301"}],"text":"The increasing number of new therapies for MS and the potential risk for a lack of response and/or serious adverse reactions make individualized therapy a high-priority for MS. Pharmacogenomics applies technologies such as gene expression profiling, single nucleotide polymorphism (SNP) screens, and proteomics in order to predict response to treatment and toxicity to drugs."}